347 related articles for article (PubMed ID: 28656060)
1. PET Tracer
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
[No Abstract] [Full Text] [Related]
2. Fasting Enhances the Contrast of Bone Metastatic Lesions in
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238
[No Abstract] [Full Text] [Related]
3. In Molecular Pursuit of Bone Metastasis by Fluciclovine PET.
Lindenberg L
Theranostics; 2017; 7(7):2065-2066. PubMed ID: 28638486
[TBL] [Abstract][Full Text] [Related]
4. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
5. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Including Bone in Dixon-Based Attenuation Correction for
Elschot M; Selnæs KM; Johansen H; Krüger-Stokke B; Bertilsson H; Bathen TF
J Nucl Med; 2018 Dec; 59(12):1913-1917. PubMed ID: 29728516
[TBL] [Abstract][Full Text] [Related]
7. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
8. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
[TBL] [Abstract][Full Text] [Related]
9. A PET/MRI study towards finding the optimal [
Elschot M; Selnæs KM; Sandsmark E; Krüger-Stokke B; Størkersen Ø; Tessem MB; Moestue SA; Bertilsson H; Bathen TF
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):695-703. PubMed ID: 27817158
[TBL] [Abstract][Full Text] [Related]
10. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.
Nakai T; Okuyama C; Kubota T; Yamada K; Ushijima Y; Taniike K; Suzuki T; Nishimura T
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1253-8. PubMed ID: 16133397
[TBL] [Abstract][Full Text] [Related]
11. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer.
Chen B; Wei P; Macapinlac HA; Lu Y
Nucl Med Commun; 2019 Sep; 40(9):940-946. PubMed ID: 31343613
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.
Chau A; Gardiner P; Colletti PM; Jadvar H
Clin Nucl Med; 2018 Jul; 43(7):e226-e231. PubMed ID: 29762238
[TBL] [Abstract][Full Text] [Related]
14. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients.
Al-Muqbel KM; Yaghan RJ; Al-Omari MH; Rousan LA; Dagher NM; Al Bashir S
Nucl Med Commun; 2016 Jun; 37(6):593-601. PubMed ID: 26813990
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
[TBL] [Abstract][Full Text] [Related]
17. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
[TBL] [Abstract][Full Text] [Related]
18. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Amino Acid/Drug Transporters for Renal Transport of [
Ono M; Baden A; Okudaira H; Kobayashi M; Kawai K; Oka S; Yoshimura H
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754421
[TBL] [Abstract][Full Text] [Related]
20. Imaging of Prostate Cancer Using Fluciclovine.
Savir-Baruch B; Zanoni L; Schuster DM
PET Clin; 2017 Apr; 12(2):145-157. PubMed ID: 28267449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
